ライフサイエンスコーパス: antithymocyte globulin

1 nal induction therapy (basiliximab or rabbit antithymocyte globulin).

2 id irradiation, cyclophosphamide, and rabbit-antithymocyte globulin.

3 were mostly cyclophosphamide with or without antithymocyte globulin.

4 ther 20 mg alemtuzumab or 6 mg per kg rabbit antithymocyte globulin.

5 men included busulfan, cyclophosphamide, and antithymocyte globulin.

6 nsity conditioning with cyclophosphamide and antithymocyte globulin.

7 ablative dosages of busulfan, melphalan, and antithymocyte globulin.

8 0 mg/kg cyclophosphamide and 90 mg/kg equine antithymocyte globulin.

9 mg/kg cyclophosphamide, and 90 mg/kg equine antithymocyte globulin.

10 isting of cyclophosphamide, fludarabine, and antithymocyte globulin.

11 1 g methylprednisolone, and 90 mg/kg equine antithymocyte globulin.

12 myelodysplasia, or renal allografts received antithymocyte globulin.

13 renal allograft recipients who had received antithymocyte globulin.

14 grade 2A rejection successfully treated with antithymocyte globulin.

15 duced-intensity conditioning, and the use of antithymocyte globulin.

16 leukocyte antigen mismatch, age, and use of antithymocyte globulin.

17 mib, methylprednisone, rituximab, and rabbit antithymocyte globulin.

18 imus, mycophenolate mofetil, prednisone, and antithymocyte globulins.

19 uccessful induction therapy using two rabbit antithymocyte globulins.

20 ate mofetil, prednisone, and, for induction, antithymocyte globulins.

21 mphoid irradiation of 80 cGy for 10 days and antithymocyte globulin 1.5 mg/kg/d for 5 days.

22 e randomly assigned to receive either rabbit antithymocyte globulin (1.5 mg per kilogram of body weig

23 e the murine monoclonal anti-CD3 antibody or antithymocyte globulin (15.2% versus 21.1%; P=0.061).

24 ence was seen between alemtuzumab and rabbit antithymocyte globulin (18% vs. 15%, P=0.63).

25 Antithymocyte globulin, 40 mg/kg of body weight, given d

26 emental thymic irradiation (7 Gy on day -1), antithymocyte globulin (50 mg/kg on days -2, -1, and 0),

27 along with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg) (n = 55) or DMT of high

28 nditioning regimen used was CYC (200 mg/kg), antithymocyte globulin (90 mg/kg), and methylprednisolon

29 gimen included cyclophosphamide (200 mg/kg), antithymocyte globulin (90 mg/kg), and, for 1 patient, t

30 ng, cyclophosphamide (120 mg/kg), and equine antithymocyte globulin (90 mg/kg).

31 with cyclophosphamide (200 mg/kg) and equine antithymocyte globulin (90 mg/kg).

32 one dose of 30 mg, in 70 patients) or rabbit antithymocyte globulin (a total of 6 mg per kilogram of

33 ession, all patients received induction with antithymocyte globulin, a brief taper of intravenous sol

34 time, delayed graft function, induction with antithymocyte globulins, acute rejection before month 3

35 A dose of 40 mg/kg per day of antithymocyte globulin administered for 4 days, 10 to 12

36 f haploidentical marrow grafts, who received antithymocyte globulin after bone marrow transplantation

37 ng regimen of total lymphoid irradiation and antithymocyte globulin allowed engraftment of the donor'

38 tion, the ATG group (13 recipients) received antithymocyte globulin, although the LOCD2b group (10 re

39 teroid withdrawal protocol; 9 of 11 received antithymocyte globulin and 2 received basiliximab induct

40 eived a conditioning regimen including horse antithymocyte globulin and aCD40/Bela.

41 included induction with a steroid taper and antithymocyte globulin and anti-CD20 monoclonal antibody

42 national study, we compared short courses of antithymocyte globulin and basiliximab in patients at hi

43 ransplantation, immunosuppression (generally antithymocyte globulin and ciclosporin), and high-dose c

44 st-line immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporin and is manifested

45 immunosuppressive therapy with drugs such as antithymocyte globulin and cyclosporine have clonal expa

46 nts with severe aplastic anemia treated with antithymocyte globulin and cyclosporine have durable rec

47 Antithymocyte globulin and cyclosporine restore hematopo

48 standard immunosuppressive regimens, such as antithymocyte globulin and cyclosporine.

49 ined a well-established adult mouse model of antithymocyte globulin and DBM treatment and show that e

50 let Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet c

51 re less than 150 and 250, respectively, with antithymocyte globulin and intravenous immunoglobulin in

52 We conclude that induction with antithymocyte globulin and maintenance immunosuppression

53 received additional immune suppression with antithymocyte globulin and methylprednisolone in the ear

54 sisted of high-dose cyclophosphamide, equine antithymocyte globulin and pretransplant thymic irradiat

55 The use of antithymocyte globulin and prolonged exposure to gancicl

56 , contributes to the therapeutic efficacy of antithymocyte globulin and suggest that time-dependent w

57 Immunosuppression included antithymocyte globulins and bone-marrow infusion then st

58 Immunosuppression with antithymocyte globulins and cyclosporine is effective at

59 89 kidney transplant recipients treated with antithymocyte globulins and prednisone.

60 With antithymocyte globulins and steroids, clinically suspect

61 n posttransplant total lymphoid irradiation, antithymocyte globulin, and a single infusion of ACI per

62 I and thymic irradiation, pretransplantation antithymocyte globulin, and immunoadsorption of anti-Gal

63 total body irradiation, thymic irradiation, antithymocyte globulin, and peritransplant CD154 blockad

64 multivariable analysis, CMV-CMI, sex, race, antithymocyte globulin, and steroid use were independent

65 nt after conditioning with cyclophosphamide, antithymocyte globulin, and thymic irradiation.

66 Selected patients respond to antithymocyte globulins, and thrombopoietin receptor ago

67 rapy agents, growth factor combinations, and antithymocyte globulin appear promising and are reviewed

68 ition of melphalan, and the incorporation of antithymocyte globulin appear to have contributed to bet

69 eroid maintenance therapy and induction with antithymocyte globulin are independent risk factors for

70 tion therapy consisting of a 5-day course of antithymocyte globulin, as compared with basiliximab, re

71 CMV disease, attributable to high levels of antithymocyte globulin at the time of T cell infusion.

72 groups based on induction immunosuppression: antithymocyte globulin (ATG) (n=85) or basiliximab (n=29

73 Antithymocyte globulin (ATG) + cyclosporine is effective

74 However, our randomized trial comparing antithymocyte globulin (ATG) and Cy was terminated early

75 otal body irradiation, cyclophosphamide, and antithymocyte globulin (ATG) and was followed by transpl

76 Eighty-two patients received rabbit antithymocyte globulin (ATG) as part of the conditioning

77 ate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clo

78 Lymphocyte depletion with antithymocyte globulin (ATG) can be complicated by syste

79 Optimizing antithymocyte globulin (ATG) dosage is critical, particu

80 C using total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) followed by the infusion of

81 ndomized clinical trial comparing ABX-CBL to antithymocyte globulin (ATG) for treatment of steroid-re

82 We previously showed that antithymocyte globulin (ATG) given with total body irrad

83 Antithymocyte globulin (ATG) has been used in allogeneic

84 Antithymocyte globulin (ATG) has recently been populariz

85 Daclizumab and antithymocyte globulin (ATG) have been shown to reduce a

86 The impact of antithymocyte globulin (ATG) in the setting of a myeloab

87 ences were not seen among patients receiving antithymocyte globulin (ATG) induction (aRR for AR, 1.16

88 rawal after liver transplantation (LT) using antithymocyte globulin (ATG) induction and rapamycin.

89 Total lymphoid irradiation (TLI) with antithymocyte globulin (ATG) is a unique regimen that pr

90 Antithymocyte globulin (ATG) is used as induction therap

91 Polyclonal antithymocyte globulin (ATG) is widely used as an anti-T

92 Moreover, combining PTCY with antithymocyte globulin (ATG) may help to reduce GVHD inc

93 udies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for redu

94 ersial, particularly regarding concerns that antithymocyte globulin (ATG) might increase HCV-related

95 We evaluated the effect of antithymocyte globulin (ATG) on anti-human leukocyte ant

96 We studied the impact of early, late, and no antithymocyte globulin (ATG) on immune reconstitution an

97 Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can b

98 iated with a clinically relevant response to antithymocyte globulin (ATG) or cyclosporine immunosuppr

99 tion or in vivo T-cell depletion with either antithymocyte globulin (ATG) or monoclonal anti-T-cell a

100 Immunosuppressive therapy with antithymocyte globulin (ATG) plus cyclosporine is an eff

101 Low-dose antithymocyte globulin (ATG) plus pegylated granulocyte

102 Depletional induction using antithymocyte globulin (ATG) reduces rates of acute reje

103 The addition of antithymocyte globulin (ATG) to a regimen of high-dose c

104 ddition of low, nondepleting doses of rabbit antithymocyte globulin (ATG) to human peripheral blood m

105 ) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-m

106 ith an NMA preparative regimen that included antithymocyte globulin (ATG) versus those that did not (

107 ed with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) were given kidney transplan

108 data support replacing BuCy2 with or without antithymocyte globulin (ATG) with Bu-Flu with or without

109 e fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine

110 ant total lymphoid irradiation (TLI), rabbit antithymocyte globulin (ATG), and a single donor blood t

111 ed the ability of the immune-depleting agent antithymocyte globulin (ATG), as well as the mobilizatio

112 erapy and 93 (>25, 386; n=3) days with added antithymocyte globulin (ATG), but did not yield toleranc

113 oning regimen--whole body irradiation (WBI), antithymocyte globulin (ATG), extracorporeal immunoadsor

114 ive nonmyeloablative protocols using TLI and antithymocyte globulin (ATG), followed by allogeneic hem

115 se using various combinations of four drugs: antithymocyte globulin (ATG), granulocyte-colony stimula

116 -lymphoid irradiation (TLI), with or without antithymocyte globulin (ATG), have been shown to develop

117 Thymoglobulin, a rabbit polyclonal antithymocyte globulin (ATG), is a widely used induction

118 s, induction with antilymphocyte globulin or antithymocyte globulin (ATG), or use of ATG or OKT3 for

119 nts receiving total body irradiation without antithymocyte globulin (ATG), whereas the relapse risk w

120 tosus, conditioned with a regimen containing antithymocyte globulin (ATG), who developed factor VIII

121 al greater than 80 days using a steroid-free antithymocyte globulin (ATG)-based induction regimen (AT

122 res of 12 patients with MDS before and after antithymocyte globulin (ATG)-based treatment by T-cell r

123 he cardiovascular consequences of polyclonal antithymocyte globulin (ATG)-induced immune modification

124 mes with steroids alone versus steroids plus antithymocyte globulin (ATG).

125 some of whom were undergoing treatment with antithymocyte globulin (ATG).

126 of groups 2 and 3 received CY combined with antithymocyte globulin (ATG).

127 Patients received immunosuppression with antithymocyte globulin (ATG)/cyclosporine (CsA) or cyclo

128 experience using dual-induction therapy with antithymocyte globulin (ATG)/daclizumab (Dac) (each with

129 ody irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclopho

130 clophosphamide (200 mg/kg) and either equine antithymocyte globulin (ATG, 90 mg/kg) or rabbit ATG (6

131 de (200 mg/kg), methylprednisolone (4 g) and antithymocyte globulin (ATG; 90 mg/kg) or myeloablative

132 s according to whether conditioning included antithymocyte globulin (ATG; n = 191) or alemtuzumab (n

133 splantation either with (n = 241) or without antithymocyte globulin (ATG; n = 491) following reduced-

134 003 to 2004 received no induction (n=4,364), antithymocyte globulin (ATG; n=4,930), interleukin-2 rec

135 orin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux,

136 otal body irradiation, cyclophosphamide, and antithymocyte globulin [ATG] with cyclosporine A and met

137 Polyclonal antihuman thymocyte rabbit IgGs (antithymocyte globulin [ATG]) are popular immunosuppress

138 (ATS) (the murine preclinical equivalent of antithymocyte globulin [ATG]) facilitates immune toleran

139 ual care (the control group was treated with antithymocyte globulin [ATG]).

140 omes after in vivo T-cell depletion (n = 584 antithymocyte globulin [ATG]; n = 213 alemtuzumab) were

141 r patients who have undergone thymoglobulin (antithymocyte globulins [ATG]) or basiliximab (BSX) ther

142 t and 19 lung transplant recipients received antithymocyte globulin (ATGAM or thymoglobulin) as induc

143 Polyclonal antithymocyte globulins (ATGs) are used clinically to pr

144 Antithymocyte globulins (ATGs) are used to prevent and t

145 Rabbit-generated antithymocyte globulins (ATGs), which target human T cel

146 Polyclonal antithymocyte globulins (AThG) are a subset of antilymph

147 reatment study, 34% of patients treated with antithymocyte globulin became transfusion independent.

148 ymic irradiation before transplantation, and antithymocyte globulin before and after transplantation.

149 cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.

150 ome received busulfan, cyclophosphamide, and antithymocyte globulin before receiving cord-blood trans

151 prophylaxis, all but 2 received serotherapy (antithymocyte globulin) before HSCT and a short course o

152 splant recipients who were prescribed rabbit antithymocyte globulin, calcineurin inhibitor, mycopheno

153 armustine, etoposide, cytarabine, melphalan)+antithymocyte globulin chemotherapeutic regimen.

154 t recipients who received induction doses of antithymocyte globulin combined with maintenance immunot

155 (700 cGy) irradiation, T cell depletion with antithymocyte globulin, complement depletion with cobra

156 alemtuzumab-based conditioning with standard antithymocyte globulin conditioning regimens, lower rate

157 er ex vivo nor in vivo T-cell depletion (eg, antithymocyte globulin) convincingly improved outcomes.

158 d elimination at 1 week, and combined rabbit antithymocyte globulin/daclizumab induction, previously

159 ipients additionally received horse anti-pig antithymocyte globulin (days -2, -1, and 0).

160 A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute

161 Treatment with antithymocyte globulin did not seem to be detrimental be

162 total body irradiation, thymic irradiation, antithymocyte globulin, donor bone marrow transplantatio

163 Ganciclovir-resistant patients received more antithymocyte globulin during induction (70+/-44 vs. 45+

164 h about 5 mg/kg of a broadly reacting rabbit antithymocyte globulin during several hours.

165 Rabbit antithymocyte globulin facilitates apoptosis of alloreac

166 Fludarabine, busulfan, and antithymocyte globulin (Fd/Bu/ATG) was associated with t

167 The regimen consisted of antithymocyte globulin, fludarabine, cyclophosphamide, a

168 herefore tested T-cell depletion with rabbit antithymocyte globulin followed by sirolimus monotherapy

169 otal lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-m

170 tations from unrelated donors and were given antithymocyte globulin for GVHD prophylaxis.

171 h anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-

172 The total amount of antithymocyte globulin given to each CD3 monitored patie

173 drugs such as tacrolimus, mycophenolate, or antithymocyte globulin go on shortage.

174 The antithymocyte globulin group and the basiliximab group h

175 The antithymocyte globulin group, as compared with the basil

176 ic CMVIG and induction with high-dose rabbit antithymocyte globulin (>10 mg/kg) were associated with

177 m immunosuppressive therapy (IST) with horse antithymocyte globulin (h-ATG) and cyclosporine (CsA) ca

178 r between the two groups, patients receiving antithymocyte globulin had a greater incidence of infect

179 g high-risk patients, alemtuzumab and rabbit antithymocyte globulin had similar efficacy.

180 Polyclonal antithymocyte globulins have been assumed to deplete or

181 re acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma ce

182 arly phase of allogeneic HCT were receipt of antithymocyte globulin (HR, 22.77 [95% CI, 4.85-101.34])

183 nce interval [CI]=1.16-1.81), induction with antithymocyte globulin (HR: 1.43, 95% CI=1.075-1.94), an

184 ely) were low and associated with the use of antithymocyte globulin in 91% of patients.

185 ired steroid therapy and one required rabbit antithymocyte globulin in addition to MMF and steroids.

186 with interleukin-2 receptor antagonists, and antithymocyte globulin in high-risk recipients.

187 onmyeloablative conditioning, and absence of antithymocyte globulin in the conditioning regimen.

188 To examine whether antithymocyte globulin-induced regulatory cells might be

189 results demonstrate that in a murine system, antithymocyte globulin induces cells with suppressive ac

190 ere enrolled in a prospective study in which antithymocyte globulin induction and 6 days of corticost

191 uired in SPK transplant recipients receiving antithymocyte globulin induction and maintenance immuno-

192 Immunosuppression consisted of antithymocyte globulin induction and maintenance with si

193 ients of intraportal islet cell grafts under antithymocyte globulin induction and mycophenolate mofet

194 ntenance prednisone in the setting of rabbit antithymocyte globulin induction and tacrolimus and siro

195 Almost all patients received antithymocyte globulin induction and were maintained on

196 Immunosuppression consisted of antithymocyte globulin induction followed by mycophenola

197 ined PAK (n=47) transplants receiving rabbit antithymocyte globulin induction from June 1998 to June

198 CI], 1.2 to 6.6; P=0.02) and those receiving antithymocyte globulin induction therapy (hazard ratio,

199 nor, thin ureters at kidney transplantation, antithymocyte globulin induction therapy, blood transfus

200 An early steroid withdrawal regimen with antithymocyte globulin induction was associated with exc

201 od II (post-August 2001) with alemtuzumab or antithymocyte globulin induction with steroid avoidance.

202 k renal transplant patients usually involves antithymocyte globulin induction with triple drug mainte

203 corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, and mycoph

204 pression consisted of quadruple therapy with antithymocyte globulin induction, tacrolimus, MMF, and p

205 corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, mycophenol

206 yclosporine and corticosteroids after rabbit antithymocyte globulin induction.

207 All patients received antithymocyte globulin induction.

208 tient received methylprednisolone and rabbit antithymocyte globulin intravenously during scalp prepar

209 Antithymocyte globulin is frequently used as a component

210 Mouse antithymocyte globulin (mATG) prevents, as well as rever

211 Induction therapy with rabbit antithymocyte globulin may achieve a short-term decrease

212 CMVIG and appropriate induction with rabbit antithymocyte globulin may be important to reduce CMV in

213 1997 using a similar induction protocol with antithymocyte globulin, mycophenolate mofetil, prednison

214 usulfan (Bu)/alemtuzumab (n = 8), and Flu/Bu/antithymocyte globulin (n = 1).

215 py was with MMF, tacrolimus, prednisone, and antithymocyte globulin (n=109) or OKT3 (n=2).

216 eukin (IL)-2-receptor antagonists (n=217) or antithymocyte globulin (n=64).

217 Thus, in both murine and human systems, antithymocyte globulins not only deplete T cells, but al

218 vidualized conditioning and serotherapy (eg, antithymocyte globulin), nutritional status, exercise, h

219 erapy with Minnesota antilymphocyte globulin/antithymocyte globulin/OKT3 in most cases and maintenanc

220 nt pretreatment with a single dose of rabbit antithymocyte globulin or alemtuzumab and posttransplant

221 Describe the safety and efficacy of antithymocyte globulin or alemtuzumab preconditioning, s

222 e fludarabine based and T cell depleted with antithymocyte globulin or alemtuzumab.

223 n the recipient are depleted by a polyclonal antithymocyte globulin or an anti-T cell immunotoxin.

224 fetil were required as well as either rabbit antithymocyte globulin or interleukin-2 receptor antibod

225 fractory cases, alternative regimens such as antithymocyte globulin or monoclonal antibody therapy ha

226 received methylprednisolone, and 11 received antithymocyte globulin or OKT3.

227 unosuppressive regimens that included rabbit antithymocyte globulin or tacrolimus/mycophenolate combi

228 hosphamide, and 6.5 mg/kg intravenous rabbit antithymocyte globulin or to receive 1.0 g/m(2) intraven

229 umab (versus no induction, anti-CD25, rabbit antithymocyte globulin, or rabbit antithymocyte globulin

230 (P = 0.046) as well as those having received antithymocyte globulin (P < 0.001) were more likely to d

231 LA-DR mismatches (P = 0.008), induction with antithymocyte globulin (P = 0.0001), and pretransplant p

232 atologic improvement after administration of antithymocyte globulin (P = 0.0015).

233 le body and thymic irradiation, splenectomy, antithymocyte globulin, pharmacologic immunosuppression

234 should be considered for a second course of antithymocyte globulin plus cyclosporin, although respon

235 enrolled in immunosuppression protocols with antithymocyte globulin plus cyclosporine for correlation

236 onsisting of busulfan, cyclophosphamide, and antithymocyte globulin plus or minus etoposide.

237 lant, and patients did not routinely receive antithymocyte globulin posttransplant.

238 mber 2008 who received induction with rabbit-antithymocyte globulin (r-ATG), alemtuzumab, or an inter

239 ategories: no-induction, alemtuzumab, rabbit antithymocyte globulin (r-ATG), and interleukin-2 recept

240 randomized for 3 different regimens: rabbit antithymocyte globulin (r-ATG)/EVR (N = 85); basiliximab

241 -) and 104 seropositive recipients receiving antithymocyte globulins (R+/ATG).

242 we generated 1:1 pairs of alemtuzumab-rabbit antithymocyte globulin (rATG) (5330 pairs) and basilixim

243 ts were treated with T cell-depleting rabbit antithymocyte globulin (rATG) (6 mg/kg, n = 17) or nonde

244 emtuzumab induction was compared with rabbit antithymocyte globulin (rATG) (Thymoglobulin [Genzyme] o

245 ategies have not been established for rabbit antithymocyte globulin (rATG) after heart transplantatio

246 Rabbit antithymocyte globulin (rATG) and horse ATG (hATG) are w

247 reatment using induction therapy with rabbit antithymocyte globulin (RATG) and intravenous immunoglob

248 Alemtuzumab and rabbit antithymocyte globulin (rATG) are commonly used for indu

249 Despite the prevalent use of rabbit antithymocyte globulin (rATG) as an induction agent in k

250 safety and efficacy of induction with rabbit antithymocyte globulin (RATG) compared with interleukin-

251 ients who received either steroids or rabbit antithymocyte globulin (RATG) for orthotopic liver trans

252 recipients who received rituximab and rabbit antithymocyte globulin (rATG) in combination as inductio

253 free immunosuppression protocol using rabbit antithymocyte globulin (RATG) induction in orthotopic li

254 Rabbit antithymocyte globulin (rATG) induction is associated wi

255 Optimal dosing of rabbit antithymocyte globulin (rATG) induction therapy in kidne

256 ge, we developed a protocol to extend rabbit antithymocyte globulin (rATG) induction therapy into the

257 5 mg versus MMF in patients receiving rabbit antithymocyte globulin (rATG) induction, mainly due to i

258 ers comparing a control group of with rabbit antithymocyte globulin (rATG) induction, rapid steroid t

259 Induction rabbit antithymocyte globulin (rATG) is largely used in renal a

260 who were randomized to receive either rabbit antithymocyte globulin (RATG) or steroids as induction t

261 ere evaluated before and after adding rabbit antithymocyte globulin (rATG) to mixed lymphocyte co-cul

262 Rabbit-derived antithymocyte globulin (rATG) treatment reduces the inci

263 single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a maintenance arm (pa

264 Thymoglobulin, rabbit antithymocyte globulin (RATG), has been shown to be effe

265 man leukocyte antigen (HLA) mismatch, rabbit antithymocyte globulin (RATG), interleukin-2 receptor an

266 proliferation by Ki-67(+) T cells in rabbit antithymocyte globulin (rATG)-treated patients the first

267 bined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG).

268 exposed (4.23%) versus not exposed to rabbit antithymocyte globulin (rATG; 0.53%; P=0.019) or SPK (9.

269 iximab (1998), daclizumab (1998), and rabbit antithymocyte globulin (rATG; 1999) replaced antilymphoc

270 ognostic influence of induction type: rabbit antithymocyte globulin (rATG; 2 mg/kg x 5)/rituximab (15

271 ed to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in living d

272 Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme) in

273 out granulocyte colony-stimulating factor or antithymocyte globulin, respectively.

274 efine the efficacy of a busulfan/fludarabine/antithymocyte globulin RIC regimen in pediatric patients

275 and consecutive LT patients receiving rabbit antithymocyte globulin+/-rituximab induction were studie

276 With the use of rabbit antithymocyte globulin+/-rituximab induction, overall lo

277 25, rabbit antithymocyte globulin, or rabbit antithymocyte globulin/rituximab) induction (P = 0.004),

278 tion of donor marrow (RR = 12.7), and use of antithymocyte globulin (RR = 6.4) or anti-CD3 monoclonal

279 ession was Tac-Pred based in nine and rabbit antithymocyte globulin-Tac based in six cases.

280 as carried out under Tac-Pred in six, rabbit antithymocyte globulin-Tac in eight, and alemtuzumab mon

281 Subjects received rabbit antithymocyte globulin, tacrolimus, mycophenolate mofeti

282 itioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cel

283 Patients who were randomized to antithymocyte globulin therapy (ATGAM, ATG) received 15

284 ipheral CD3 lymphocytes to rationally adjust antithymocyte globulin therapy in this patient populatio

285 CD3 monitoring of antithymocyte globulin therapy in thoracic organ recipie

286 imary kidney transplant recipients comparing antithymocyte globulin (Thymoglobulin) (group A, N=43) v

287 eatment with approximately 5 mg/kg of rabbit antithymocyte globulin (Thymoglobulin) in the hours befo

288 Recipients were treated with 7 doses of antithymocyte globulin (Thymoglobulin, day 1 to 9), siro

289 omized, international study comparing rabbit antithymocyte globulin (TMG) and basiliximab (BAS) induc

290 rotocol applied including plasmapheresis and antithymocyte globulin treatment as well as cyclophospha

291 th or without endarteritis responded to OKT3/antithymocyte globulin treatment equally well (61% versu

292 Although in vitro antithymocyte globulin treatment resulted in a dramatic

293 the patients) was defined as requirement for antithymocyte globulin treatment within 2 weeks after co

294 Age, history of antithymocyte globulin use, smoking, and history of canc

295 with Aspergillus colonization, use of rabbit antithymocyte globulin was associated with 4-fold risk o

296 -2-receptor induction with daclizumab versus antithymocyte globulin was independently associated with

297 ortional hazard model, treatment with rabbit antithymocyte globulin was significantly associated with

298 Historically, antithymocyte globulin was used when patients did not re

299 With CD3 monitoring, the doses of antithymocyte globulin were reduced from 10-15 mg/kg to

300 nduction therapy (antilymphocyte globulin or antithymocyte globulin), whereas LRD recipients did not.